お知らせ • Dec 03
BioElectronics Corporation Appoints Sree Koneru to Its Board of Directors BioElectronics Corporation announced that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD. Dr. Koneru is Director of Program Management for a contract manufacturing organization that specializes in the design & development of wearable and implantable active electronic medical devices. In his previous role, Sree served as the VP of Product Development for BioElectronics Corporation, where he was responsible for prototype development, physiological testing/clinical evaluation, and regulatory submissions, culminating in several approvals from the US FDA and a CE marking. He also managed the product life cycle from conception to retail launch for domestic and international channel partners. Sree obtained his doctoral degree in Biomedical Engineering ('15) from the State University of New York at Binghamton, NY- USA. He has a background in bringing Neuromodulation (Electroceuticals) medical devices to market, with research expertise in investigating physiological responses (prototype development and clinical research) of pulsed radiofrequency electromagnetic fields. His vision is to be an industry leader in developing transcutaneous, percutaneous, implantable, and electromagnetic neuromodulation technologies, intended to treat chronic diseases. お知らせ • Mar 27
BioElectronics Corporation Announces the Results and Publication of A Canine Arthritis Study BioElectronics Corporation announced the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT) device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint. Two outcomes measuring the dog's quality of life were assessed: subjectively determined changes in eight behaviors associated with discomfort, and objectively determined changes in passive range of motion (PROM). BioElectronics' Model 088 device was secured near the cervical region of the dog's spine. PROM measures were taken at baseline and day 14. Behavioral measures were taken daily. Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Most changes occurred within the first 8 days of treatment. Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs. This is due to the constant wearing away of the cartilage from dogs running, jumping, and other continuous exercise. The prevalence of osteoarthritis can be as high as 20% in dogs more than a year old, with middle-aged and older dogs being at higher risk. dogs that are diagnosed with arthritis tend to be lethargic, have difficulty moving from a sitting or lying position, cracking joints, stiffness, muscle wastage, and visible pain. Current treatment options for arthritis are typically NSAIDs given alone or in combination with other disease-modifying agents. In recent years, chronic use of NSAIDs has been linked to numerous side effects, including gastrointestinal (GI) bleeding, and renal and hepatic dysfunction. Anti-inflammatory drugs such aspirin and ibuprofen may also result in side effects, such as GI bleeding. BioElectronics Model 088 applied at the cervical spine level, may have the potential to significantly improve the quality of life for dogs and other small domestic animals with OA. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market. お知らせ • Feb 23
Bioelectronics Corporation Announces the Publication of Pilot Study Results BioElectronics Corporation announced the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device. The study design had patients first wear BioElectronics' Model 088 device (about 1/2 wearing the sham device and the remaining wearing the active device) on the residual part of the limb for 28 days. After 28 days, the patient began wearing the opposite device, i.e., the sham group wearing the active device, and the treatment group wearing the active device, again for 28 days. Three major measures were obtained for both phantom pain and residual pain along with a global assessment of change in both phantom and residual pain before, during, and after each 28 days. The researchers presented their findings in a series of graphs over time depending on whether the patient was wearing the sham or active device. When wearing the sham device, patients reported, on average, no change in the median phantom limb pain or pain in the residual limb. They also reported no median change in their global assessment of pain. In contrast, when the patients were wearing the active device, they reported, on average, a 40% to 50% decrease in the median measures for both average and worst residual and phantom limb pain by day 7 and this reduction continued through day 28. Moreover, a majority of patients, when wearing the active device, reported the highest level of global change in residual pain, i.e., "very much better" by day 21 and this continued through day 28. This measure on the phantom limb pain was also positive, with the majority of subjects reporting being " much better". The researchers conclude that further study is warranted given that an identified beneficial treatment effect is associated with using BioElectronics' Model 0 88 in the setting of a low-cost and low-risk intervention. Currently, there are 1.6 million people in the United States who are living with the loss of a limb. Due to the rising number of people who have diabetes, a major cause of amputations, it is estimated that the number of amputations could grow to as many as 3.6 million by 2050. More than 7 in 10 people who have had an arm or leg amputated have pain in the lost limb, which they perceive as still present. Nearly 4 in 10 have severe pain, and many also report depression and anxiety linked with phantom limb pain making it hard to sleep, work, and take part in family and social activities. People who have phantom limb pain are often prescribed medications, including opioids, but opioid medications are effective in only about half of these patients and can also have serious side effects, including the risk of addiction. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device to address this significant unmet medical need. お知らせ • Dec 17
BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail Market BioElectronics Corporation announced that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets. お知らせ • Nov 07
BioElectronics' ActiPatch Therapy To Be Marketed By DonJoy Advantage BioElectronics Corporation announced the execution of a commercial partnership agreement with Scott Specialties Inc. to bring their innovative pain management devices to the retail consumer healthcare marketplace under the DonJoy (DJO www.djoglobal.com) Advantage product line. This commercial partnership will leverage the ActiPatch's broad indications for use and offer an active-passive treatment combination product to treat pain, increase physical functionality and improve overall quality of life. The new products will be marketed under DJO's DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap," powered by ActiPatch".